Vitamin E
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BEROCCA PN | — | 1947-07-28 | fda.gov ↗ |
Trials 117 · started per year
Also used as a comparator or background therapy in 47 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07121127 Background | Jul 2026 → Aug 2029 expected | age-related macular degeneration | Zhiming Yan | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06105060 Comparator | Dec 2023 → Jun 2024 | metabolic dysfunction-associated steatohepatitis | Beni-Suef University | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01578473 Comparator | May → Jul 2013 | Peyronie disease | Men's Health Boston | Completed | No outcome recorded |
| Phase 1 | NCT01700426 Comparator | Jun 2011 → Sep 2013 | iron deficiency anemia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06871904 Background | Apr → Dec 2025 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 1/2 | NCT02181348 Comparator | Nov 2008 → Oct 2011 | anemia | Aga Khan University | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07303803 Background | Jan 2026 → Dec 2030 expected | metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06321991 Comparator | Feb 2024 → Mar 2027 expected | palmar fibromatosis | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| Phase 2 | NCT04801849 Comparator | Aug 2022 → Mar 2025 | NAFLD1, metabolic dysfunction-associated steatohepatitis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT06677788 Comparator | Apr 2022 → Sep 2024 | metabolic dysfunction-associated steatohepatitis | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05200663 Comparator | Oct 2021 → Oct 2022 | oligoasthenoteratozoospermia | Sharif Medical Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT05573204 Comparator | Sep 2021 → Oct 2026 expected | metabolic dysfunction-associated steatohepatitis | Tanta University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04071977 Comparator | Mar 2020 → Oct 2021 | diabetes mellitus, diabetic retinopathy | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT03669133 Comparator | Oct 2019 → Mar 2021 | HIV infectious disease, metabolic dysfunction-associated steatohepatitis | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT03968042 Background | Jun 2019 → Dec 2021 | brain injury | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT01792115 Comparator | May 2013 → Aug 2019 | fatty liver disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT01897792 Comparator | May 2013 → Feb 2015 | bacterial pneumonia, blood coagulation disease | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 2 | NCT02058212 Comparator | Mar → Oct 2013 | endometriosis | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT01822405 Comparator | Jul 2010 → Jul 2013 | — | Hospital Universitario de Canarias | Unknown | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT05906498 Comparator | Dec 2022 → Nov 2023 | psoriasis | Badr University | Unknown | No outcome recorded |
| Phase 3 | NCT04007874 Comparator | Sep 2019 → Dec 2024 | migraine disorder | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03755700 Comparator | Nov 2018 → Dec 2019 | acute coronary syndrome, coronary artery disorder | Rajaie Cardiovascular Medical and Research Center | Unknown | No outcome recorded |
| Phase 3 | NCT02070679 Comparator | Feb 2014 → May 2015 | acute subendocardial myocardial infarction, intermediate coronary syndrome | Urmia University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02714543 Comparator | Nov 2013 → Aug 2015 | oral submucous fibrosis | The Oxford Dental College, Hospital and Research Center, Bangalore, India | Completed | No outcome recorded |
| Phase 3 | NCT01384578 Comparator | Jul 2011 → Nov 2013 | metabolic dysfunction-associated steatohepatitis | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
| Phase 3 | NCT01266928 Comparator | Jan → Nov 2011 | preterm premature rupture of the membranes | Erzincan Military Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01935817 Comparator | Jun 2010 → Dec 2012 | fibrotic liver disease | University of Catania | Completed | No outcome recorded |
| Phase 3 | NCT01957319 Comparator | Feb 2010 → Jul 2013 | depressive disorder | University of Catania | Completed | No outcome recorded |
| Phase 3 | NCT00740714 Background | Dec 2008 → Aug 2011 | Parkinson disease | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 3 | NCT00211562 Comparator | Oct 2005 → Jan 2006 | schizophrenia | Augusta University | Terminated | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT06926712 Comparator | Jun 2025 → Jun 2026 overdue | respiratory system disorder | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05813249 Comparator | Feb 2023 → Feb 2024 | NAFLD1 | Zagazig University | Completed | No outcome recorded |
| Phase 4 | NCT04977661 Comparator | Feb → May 2020 | metabolic dysfunction-associated steatohepatitis | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT03176966 Comparator | Sep 2016 → Oct 2021 | cirrhosis of liver | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01720719 Comparator | May 2013 → Dec 2016 | diabetes mellitus, fatty liver disease, hyperlipidemia | Xin Gao | Unknown | No outcome recorded |
| Phase 4 | NCT00431691 Comparator | Sep 2006 → Dec 2007 | escherichia coli infection, retinal disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07391267 Background | Feb 2026 → Dec 2028 expected | chronic kidney disease, metabolic dysfunction-associated steatotic liver disease | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT05410093 Comparator | Feb 2022 → Jul 2024 | primary ovarian failure | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| — | NCT06274216 Comparator | Sep 2021 → Mar 2022 | — | Ziauddin University | Completed | No outcome recorded |
| — | NCT06409546 Comparator | Apr 2020 → Dec 2023 | osteonecrosis of the jaw | University of Catania | Completed | No outcome recorded |
| — | NCT04664010 Background | Feb 2020 → Sep 2022 | COVID-19 | Xi'an International Medical Center Hospital | Completed | No outcome recorded |
| — | NCT04463459 Comparator | Oct 2019 → Jul 2020 | breast cancer | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| — | NCT03659058 Comparator | Mar 2016 → Aug 2018 | fibrotic liver disease | Zagazig University | Completed | No outcome recorded |
| — | NCT03274596 Comparator | Mar 2013 → Oct 2015 | retinopathy of prematurity | Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes | Completed | No outcome recorded |
| — | NCT01279434 Comparator | Jan → Mar 2012 | metabolic dysfunction-associated steatohepatitis | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
| — | NCT00914576 Comparator | Apr 2011 → Jul 2013 | — | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00893724 Comparator | Jun 2009 → Aug 2011 | diabetic macular edema, wet macular degeneration | Mid-Atlantic Retina Consultations, Inc. | Unknown | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 170 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vitamin E | “with daily multivitamins [vitamin A (300 microg, as retinol palmitate), vitamin E (6 mg tocopherol equivalents), vitamin B-12 (0.9 microg), vitamin C (15 mg), riboflavin (0.5...” PMID 19535425 ↗ Jun 2009150“Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full...” NCT03876704 ↗ “Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency...” NCT01897792 ↗ “total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium...” NCT00808470 ↗ “It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide...” NCT03702374 ↗ “Anti-oxidants such as N-acetylcysteine (NAc), Vitamin C (ascorbic acid) (VitC) and Vitamin E (alpha-tocopherol) (VitE) are potent FRS 'scavengers', which means they could be...” NCT02629536 ↗ “SM Fibro (Alpha lipoic acid 50mg, Beta-carotene 10mg, Elemental copper 1mg, Elemental selenium 75mcg, Lycopene 5mg, Vitamin E 10 IU, Zinc sulphate 27.45mg in form of the...” NCT02714543 ↗ “Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU,...” NCT02421887 ↗ “The purpose of this pilot study is to investigate the possibility that H.pylori infection alters the bioavailability of the dietary antioxidants: vitamin C, and vitamin E.” NCT00303160 ↗ “(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks” NCT02062034 ↗ “combined with an antioxidant complex composed of Phytexcell Liquorice extract (Glycyrrhiza glabra), Resveratrol bioferment, and Vitamin E (tocopherol)” NCT07301515 ↗ “The purpose of this study is to examine whether vitamin E (DL-alpha-tocopherol) supplementation will reduce the progression of early atherosclerosis” NCT00114387 ↗ “Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.” NCT01082003 ↗ “N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100” NCT02171104 ↗ “capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)” NCT01266928 ↗ “Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.” NCT00135707 ↗ “oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months” NCT04640324 ↗ “containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg” NCT00914576 ↗ “Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU” NCT00844792 ↗ “Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses” NCT04244630 ↗ “Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)” NCT00063622 ↗ “T1 group participants were taking 200mg/day of Vitamin E supplementation once a day along with conventional medicines” NCT07715643 ↗ “Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months” NCT01822405 ↗ “daily treatment with both vitamin C (1,000 mg) and vitamin E (400 International Units) or placebo.” PMID 18055726 ↗ Dec 2007 “Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day)” NCT02368457 ↗ “Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU” NCT03228238 ↗ “Fu's subcutaneous needling with oral Vitamin C and vitamin E supplements” NCT07121127 ↗ “Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months” NCT05573204 ↗ “Antioxidants consisted of a combination of vitamin E and vitamin C.” NCT00000555 ↗ “patients will receive Vitamin E 400 mg twice daily for 6 months.” NCT06105060 ↗ “Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E” NCT00744549 ↗ “Patients take vitamin E capsule and folic acid every day.” NCT04664010 ↗ “vitamin A 0.9 mg, vitamin E 100 mg, and vitamin C 50 mg)” PMID 18296460 ↗ Feb 2008 “Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg” NCT03659058 ↗ “Tocopherol (Vitamin E) has antioxidant properties.” NCT03723291 ↗ “Pioglitazone (thiazolidinedione) and vitamin-E” NCT07391267 ↗ “30 mg vitamin E \[D-α-tocopherol acetate\]” NCT01437826 ↗ “vitamin E (DL-alpha tocopherol 30 mg)” NCT04071977 ↗ “Dietary Supplement: vitamin E” NCT03674385 ↗ “Will take vitamin E 800mg/day” NCT06915701 ↗ “400 IU of Vitamin E (orally)” NCT00860743 ↗ “vitamin E 150 IU” NCT00963131 ↗ “vitamin E 100IU” NCT00431691 ↗ “Vitamin E” NCT03358524 ↗ |
| Known as | Alfa-Tocoferol | “Effects of Vitamin E (Alfa-Tocoferol) Supplementation” NCT03358524 ↗ |
| Known as | alfa-tocopherol | “Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months” NCT01822405 ↗1“Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day)” NCT02368457 ↗ |
| Known as | all rac-α-tocopheryl acetate | “Individual supplements of selenium (200 μg per day from L-selenomethionine) and vitamin E (400 IU per day of all rac-α-tocopheryl acetate).” PMID 25232809 ↗ Jan 2015 |
| Known as | alpha tocopherol | “We plan to test the efficacy of alpha-tocopherol (vitamin E), a potent inhibitor of the protein kinase C pathway in vascular endothelial growth factor (VEGF) induced vascular...” NCT00021645 ↗3“Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients'...” NCT00000173 ↗ “Anti-oxidants such as N-acetylcysteine (NAc), Vitamin C (ascorbic acid) (VitC) and Vitamin E (alpha-tocopherol) (VitE) are potent FRS 'scavengers', which means they could be...” NCT02629536 ↗ “Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)” NCT03358524 ↗ |
| Known as | DL-alpha tocopherol | “It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide...” NCT03702374 ↗ |
| Known as | RRR alpha tocopherol acetate | “capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)” NCT01266928 ↗ |
| Known as | rrr- -tocopherol | “Following that, all patients will be randomized to treatment with 3 different doses of natural vitamin E (rrr- -tocopherol at 200, 400 or 800 IU/d) for 24 weeks.” NCT01792115 ↗ |
| Known as | tocopherol | “13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)” NCT00002586 ↗18“Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU” NCT03228238 ↗ “800 IU tocopherol (400 IU morning and night)” NCT06055257 ↗ “Vitamin E (tocopherol)” NCT07301515 ↗ |
| Known as | Tocopherol Acetate | “• Vitamin E (Tocopherol Acetate): This intervention uses vitamin E, another antioxidant, thought to reduce inflammation and support tissue repair, potentially improving the...” NCT06847880 ↗ |
| Known as | vitamin E 400 IU/day brand name Natural | “vitamin E 400 IU/day brand name Natural” NCT01597765 ↗ |
| Known as | Vitamin E [(all-rac)-α-tocopheryl acetate] | “Vitamin E [(all-rac)-α-tocopheryl acetate]” NCT04198805 ↗ |
| Known as | VitE | “Anti-oxidants such as N-acetylcysteine (NAc), Vitamin C (ascorbic acid) (VitC) and Vitamin E (alpha-tocopherol) (VitE) are potent FRS 'scavengers', which means they could be...” NCT02629536 ↗4“Existing clinical trials on omega-3 and vitamin E (Vit E) are sometimes questioned due to using omega-6 fatty acids as placebo and neglecting omega-6 fatty acid intake in the diet.” NCT00399282 ↗ “We recently reported that Hydroxytyrosol (HXT) and Vitamin E (VitE) may improve oxidative stress, insulin resistance, and steatosis in children with biopsy-proven NAFLD.” PMID 33060043 ↗ Oct 2020 “Group 1 received vitamin C (Vit C), Group 2 vitamin E (Vit E), Group 3 n-acetylcysteine (NAC), Group 4 melatonin (MT) and group 5 no treatment.” PMID 37174730 ↗ May 2023 “Drug: Vit E” NCT05573204 ↗ |
| Known as | α-tocopherol | “Treatment with vitamin E (α-tocopherol, αT), a lipid-soluble antioxidant, improves liver injury but also decreases steatosis, thought to be upstream of OS, through an unknown mechanism.” PMID 32920226 ↗ Sep 20202“To investigate whether selenium and/or vitamin E (α-tocopherol) supplementation reduces the risk of recurrence and progression.” NCT00553345 ↗ “800 IU/d of vitamin E (α-tocopherol)” PMID 22431837 ↗ Jul 2012 |
| Action | Inhibit | “vitamin E inhibits GDH activity” NCT04984798 ↗ |
| Modality | Other / unclassified | “antioxidant supplementation with vitamins C and E” PMID 20375405 ↗ Apr 2010 |
| Route | Oral | “daily treatment with oral high-dose vitamin E (1600 units) or placebo” NCT00021645 ↗ |